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Pharmacokinetics- Pharmacodynamics of  
High- Dose Ivermectin with Dihydroartemisinin- 
Piperaquine on Mosquitocidal Activity and  
QT- Prolongation (IVERMAL)
Menno R. Smit1, Eric O. Ochomo2, David Waterhouse1, Titus K. Kwambai1,2,3, Bernard O. Abong’o2,  
Teun Bousema4,5, Nabie M. Bayoh6, John E. Gimnig6, Aaron M. Samuels6, Meghna R. Desai6,  
Penelope A. Phillips-Howard1, Simon K. Kariuki2, Duolao Wang1, Feiko O. ter Kuile1, Stephen A. Ward1 
and Ghaith Aljayyoussi1
High- dose ivermectin, co- administered for 3 days with dihydroartemisinin- piperaquine (DP), killed mosquitoes 
feeding on individuals for at least 28 days posttreatment in a recent trial (IVERMAL), whereas 7 days was predicted 
pretrial. The current study assessed the relationship between ivermectin blood concentrations and the observed 
mosquitocidal effects against Anopheles gambiae s.s. Three days of ivermectin 0, 300, or 600 mcg/kg/day plus DP 
was randomly assigned to 141 adults with uncomplicated malaria in Kenya. During 28 days of follow- up, 1,393 
venous and 335 paired capillary plasma samples, 850 mosquito- cluster mortality rates, and 524 QTcF- intervals were 
collected. Using pharmacokinetic/pharmacodynamic (PK/PD) modeling, we show a consistent correlation between 
predicted ivermectin concentrations and observed mosquitocidal- effects throughout the 28- day study duration, 
without invoking an unidentified mosquitocidal metabolite or drug- drug interaction. Ivermectin had no effect on 
piperaquine’s PKs or QTcF- prolongation. The PK/PD model can be used to design new treatment regimens with 
predicted mosquitocidal effect. This methodology could be used to evaluate effectiveness of other endectocides.
Mass drug administration (MDA) with the long- acting antimalar-
ial dihydroartemisinin- piperaquine (DP) is being evaluated in sev-
eral malaria endemic countries for malaria transmission reduction 
and elimination.1–3 Ivermectin is an antiparasitic drug, which also 
kills mosquitoes feeding on recently treated individuals. Adding iv-
ermectin to DP has been proposed as an innovative tool to increase 
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WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Ivermectin has been shown, in vitro and in vivo, to kill ma-
laria mosquitoes after feeding on human blood. Previous clinical 
studies showed an effect for 7 days posttreatment. A recent clini-
cal trial showed a prolonged effect for at least 28 days 
posttreatment.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Using data from the recent trial, this study explored the PK/
PD relationship between ivermectin (when co- administered 
with the antimalarial DP) and the observed mosquitocidal ef-
fects, in order to understand whether an unidentified metabolite 
or an ivermectin- piperaquine drug interaction could be contrib-
uting to the prolonged effect.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 The study shows a time- independent PK/PD relationship be-
tween ivermectin exposure in individuals and its mosquitocidal 
activity, without the need to invoke unidentified variables, such 
as an active metabolite or a drug- drug interaction.
HOW MIGHT THIS CHANGE CLINICAL 
PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
 A comprehensive PK/PD model able to predict the mosqui-
tocidal effect of varying ivermectin regimens in this population 
can be utilized in guiding future studies and mass drug adminis-
tration for malaria elimination programs.
Study Highlights
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Table 1 Primary and secondary PK parameters of ivermectin and piperaquine
Parameter
Ivermectin 
sequential 
PK/PD model
Ivermectin 
simultaneous 
PK/PD model Piperaquine
Median (p5–p95) ± interindividual 
variability (%)
Median (p5–p95) ± interindividual 
variability (%)
Median (p5–p95) ± interindividual 
variability (%)
V/F (L) 147.0 
(36.2–582.0) × (WT/60) ± 103.0
161.7 
(70.9–760.4) × (WT/60) ± 112.7
803.7 
(149.1–1,999) × (WT/60) ± 69.0
CL/F (L/hour) 9.6 (6.5–14.6) × (WT/60)0.75 ± 39.1 10.9 (6.6–26.1) × (WT/60)0.75 ± 57.4 97.1 
(20.0–177.3) × (WT/60)0.75 ± 49.1
ka (hour
−1) 0.22 (0.082–1.79) ± 157.1 0.474 (0.15–6.93) ± 163.5 1 (Fixed)
Q1/F (L/hour) 19.0 (7.7–113.1) ± 104.7 21.1 (9.7–116.4) ± 100.5 1,017.0 (197.5–4,079) ± 87.5
VP1/F (L) 1,148.1 (413.1–3,845) ± 86.6 612.4 (253.0–1,879) ± 82.1 3,796 (415.1–14,918) ± 165.8
Q2/F (L/hour) NA NA 156.4 (32.6–545.7) ± 82.8
VP2/F (L) NA NA 35,993 (7,586–146,968) ± 96.2
Capillary/venous 
ratio
1.32 (1.1–1.6) ± 18.7 1.33 (0.98–1.63) ± 29.1 1.55 (1.1–2.8) ± 36.1
Secondary parameters
Cmax (ng/mL)
All subjects NA NA 252.4 (95.5–1,072.5)
0 mcg/kg/day 
IVM arm
NA NA 250.1 (99.4–727.7)
300 mcg/kg/
day IVM arm
64.1 (29.7–129.9) 69.4 (34.1 –196.3) 263.6 (84.6–1,268.2)
600 mcg/kg/
day IVM arm
105.2 (44.5–482.5) 118.9 (45.2–455.1) 246.2 (98.8–990.1)
Tmax (hour) after last dose
All subjectsa 4.8 (0.58–8.7) 2.9 (0.46–7.8) 1.4 (1.1–3.6)
0 mcg/kg/day 
IVM arm
NA NA 1.4 (1.1–3.5)
300 mcg/kg/
day IVM arm
5.0 (1.4–8.8) 3.9 (0.75–7.6) 1.4 (1.1–3.0)
600 mcg/kg/
day IVM arm
3.5 (0.40–7.5) 2.3 (0.43–8.2) 1.5 (1.1–3.8)
t1/2 (hour)
All subjectsa 4.9 (1.9–12.9) 3.1 (0.93–11.4) 17.7 (2.6–81.8)
0 mcg/kg/day 
IVM arm
NA NA 18.2 (5.7–89.8)
300 mcg/kg/
day IVM arm
5.1 (2.2–12.6) 2.9 (1.1–7.8) 17.2 (2.8–94.6)
600 mcg/kg/
day IVM arm
4.7 (1.7–12.5) 3.2 (0.90–8.5) 17.9 (1.5–42.3)
AUC0–28 days (hour/mcg/mL) 
All subjects NA NA 21.4 (6.3–47.9)
0 mcg/kg/day 
IVM arm
NA NA 21.3 (10.4–44.9)
300 mcg/kg/
day IVM arm
5.5 (2.5–8.3) 5.0 (1.6–8.3) 23.7 (6.9–49.7)
600 mcg/kg/
day IVM arm
10.0 (1.7–22.3) 9.3 (2.1–25.0) 21.2 (6.5–46.5)
Ivermectin parameters are reported using either the sequential PK/PD model (where PK analysis was done on venous and capillary PK data only) or the 
simultaneous PK/PD model (where PK/PD analysis was performed simultaneously on venous and capillary exposure data as well as PD outputs defined as 
corresponding mosquito mortality rates for each venous sample).
AUC, area under the curve; IVM, ivermectin; PD, pharmacodynamic; PK, pharmacokinetic; NA, not available; Tmax, time of maximum plasma concentration; t1/2, 
terminal half- life; WT, bodyweight.
aFor ivermectin models, only subjects in the ivermectin arms.
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the impact of MDA for malaria.4 However, the single dose of 150–
200 mcg/kg ivermectin used for onchocerciasis and lymphatic fil-
ariasis control has only a small and short- lived effect (< 7 days) on 
mosquito mortality.5 Ivermectin is documented to be remarkably 
well tolerated, even up to doses of 2,000 mcg/kg.6,7
In a recent randomized, double- blind, placebo- controlled 
trial in western Kenya, ivermectin 300 and 600 mcg/kg/day, co- 
administered for 3 days with DP, were shown to kill mosquitoes 
feeding on individuals for at least 28 days posttreatment.8 This was 
significantly longer than the 7- day effectiveness expected based 
on the predicted time ivermectin would remain above the in vitro 
median half- maximal lethal concentration (LC50) for Anopheles 
gambiae in pretrial simulations.5 Two possible explanations are 
an unidentified mosquitocidal metabolite with a longer active 
half- life than the parent compound ivermectin or a drug- drug in-
teraction that results in a slower clearance of ivermectin from the 
circulation. As ivermectin and piperaquine are both metabolized 
by cytochrome P450 3A4 (CYP3A4), it has been hypothesized 
that an interaction could occur.5 Using the trial data, the current 
pharmacokinetic (PK) and pharmacodynamic (PD) analysis aimed 
to determine whether a drug interaction or an unidentified iver-
mectin metabolite could be contributing to the prolonged mosqui-
tocidal effect of ivermectin.
RESULTS
Ivermectin PK
Ivermectin PKs were best described by a two- compartment oral 
absorption model (Figure S1, Table S1). The initial sequential 
model, utilizing only plasma concentration data to fit the PK data, 
resulted in the parameters described in Table 1. Goodness- of- fit 
plots are shown in Figure 1 (observed capillary- venous plots are 
shown in Figure S2). In the ivermectin arms posttreatment, con-
centrations were below the limit of quantification (BLOQ) for 
277 of 805 (34.4%) venous and 44 of 224 (19.6%) capillary sam-
ples, predominantly at later time points (Table S2).
The subsequent simultaneous PK/PD model resulted in re-
markably similar PK parameters to the initial sequential approach 
(Table 1), meaning the PD element did not disturb the PK predic-
tion, which supports the notion that it is unnecessary to invoke an 
active metabolite to explain the PD output of ivermectin.
Piperaquine PK
Piperaquine PKs were best described using a three- compartment 
oral absorption model (Figure S1, Table S1), resulting in the pa-
rameters displayed in Table 1. Concentrations were BLOQ for 3 
of 1,248 (0.2%) venous and 0 of 333 (0%) capillary posttreatment 
samples (Table S2). Goodness- of- fit graphs, including both capil-
lary and venous concentrations, are shown in Figure 2 (observed 
capillary- venous plots are shown in Figure S2). A visual predictive 
check (VPC), incorporating variation in patient weights, resulted 
in a profile that accurately fits the observed population PK data 
(Figure 2e). Post hoc analysis showed that piperaquine PK was not 
influenced by ivermectin with area under the curve (AUC), peak 
plasma concentration (Cmax), terminal half- life (t1/2; Table 1) and 
the overall PK profile (Figure 2f) showing no differences across 
all three study arms.
Ivermectin PD
PD analysis of ivermectin activity was performed initially by 
building an exposure- effect relationship between pooled observed 
venous ivermectin concentrations in patients and the correspond-
ing mosquitocidal activity of each blood sample (Figure 3a). This 
generated ivermectin’s predicted half- maximal effective concen-
tration (EC50) of 11.3 ng/mL and maximal mosquito mortality 
rate (maximum effect (Emax) + minimum effect (Emin)) of 48.8 
deaths per 100 mosquito days observed (an incidence density rate). 
Baseline mortality rate (Emin) was fixed to 3.7 deaths/100 days 
based on mortality rates observed in 392 mosquito clusters feed-
ing on ivermectin- free blood from baseline and control samples.
The relationship between mosquitocidal activity and pooled 
predicted ivermectin concentrations from the sequential PK/
PD model (including 321 BLOQ venous and capillary concen-
trations that were predicted but not observed) resulted in a sim-
ilar predicted PD response, compared to analyzing observed data 
only (Table 2 and Figure 3b). A sequential population method, 
incorporating individual PK parameters (assessed previously) and 
individuals’ corresponding PD output, gave similar results: pre-
dicted median maximal mosquito mortality rate (Emax + Emin) of 
57.3 (p5–p95: 42.1–68.8) deaths per 100 mosquito days, median 
EC50 of 20.5 ng/mL (p5–p95: 6.1–49.7), and median Emin of 3.84 
(p5–p95: 3.6–4.4) deaths per 100 mosquito days. Finally, the si-
multaneous PK/PD model resulted in PD parameters that are very 
similar to those obtained from utilizing the sequential models or 
observed data only (Table 2 and Figure 3c).
The relationship between ivermectin exposure and its mosqui-
tocidal effect was investigated separately for each day of follow- up 
(days: 2 + 4 hours, 7, 10, 14, 21, and 28). As most samples beyond 
day 14 resulted in unquantifiable concentrations (BLOQ), which 
would have restricted the ability of PD analysis, predicted con-
centrations from the sequential PK model (using PK data from all 
Figure 1 Ivermectin pharmacokinetic model (sequential approach) using venous and capillary concentrations: goodness- of- fit and simulation. 
(a) Ivermectin individual predicted concentrations (n = 1,029) vs. observed concentrations (n = 708) (slope = 0.98, R2 = 0.8652).  
(b) Ivermectin population predicted concentrations vs. observed concentrations (slope = 0.81, R2 = 0.5793). (c) Weighted residual error 
distribution of predicted vs. observed ivermectin concentrations over time (mean = −0.23 over 28 days) (dashed black line = locally weighted 
scatterplot smoothing (LOESS) curve fit through residuals). (d) Weighted residual error distribution of predicted vs. observed ivermectin 
concentrations over predicted ivermectin concentration (mean = −0.23 over a range of 1–353 ng/mL; dashed black line = LOESS curve fit 
through residuals). (e) Observed ivermectin venous concentrations (gray circles) with predicted concentrations for those unobserved (gray 
squares), overlaid with simulation of ivermectin 300 mcg/kg/day for 3 days (solid black line = median; dashed gray lines = 5% and 95% 
percentiles; shaded gray area = 95% confidence interval for the percentiles). (f) Similar to e with ivermectin 600 mcg/kg/day for 3 days. IVM, 
ivermectin; conc., concentration; lower limit of quantification, 5 ng/mL (horizontal gray line). Simulations included 1,000 individuals of 60 kg 
bodyweight.
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days) were used for PD modeling; this was justified as predicted 
concentrations matched observed values accurately (Figures 1a 
and 3b). Figure 4 shows the relationship between predicted iver-
mectin exposure and mosquito mortality rate at each study visit. 
The results indicate that the mosquito mortality rate has the 
same relationship with predicted ivermectin concentration at all 
 posttreatment feeding days of the study, including days 21 and 28 
when most ivermectin exposures were BLOQ. There is no effect 
of time posttreatment on the shape of the sigmoidal relationship 
between predicted ivermectin concentration and observed mortal-
ity rate. Similar to this sequential PK/PD approach, the simulta-
neous PK/PD model showed no bias over time in residual analysis 
of PD predictions; meaning ivermectin’s concentration- effect rela-
tionship (i.e., EC50 and Emax) was consistent throughout the study 
 duration (Figure S4).
Mosquito mortality was also analyzed as a proportion (%) to cal-
culate the ivermectin concentration able to kill 50% of mosquitoes 
by a specific time point (LC50), unadjusted and adjusted for base-
line mortality (Figure S3 and Table S3).
Ivermectin PK/PD simulation
A VPC of the PK/PD simulation did not show any bias in compar-
ison with observed PD data in either arm of the study (Figure 5).
Piperaquine PD
Piperaquine’s effect upon QTcF was analyzed using a conven-
tional linear model as well as a dynamic Emax model. Using the 
linear model, piperaquine resulted in a mean QTcF- prolongation 
of 3.71 ms (95% confidence interval (CI): 3.12–4.29) per 100 ng/
mL with a baseline intercept of 6.76 ms (95% CI: 4.99–8.53) 
(Figure S5). Using the dynamic Emax population model, that was 
simultaneously fitted with piperaquine PK using Pmetrics, we 
show that from a median baseline QTcF- interval of 399.3 ms (p5–
p95: 377.5–416.3) the maximal ΔQTcF- interval was estimated 
at 53.5 ms (31.1–122.9), resulting in a maximal QTcF- interval 
of 449.8 ms (415.1–520.0). The median concentration required 
to achieve an effect half- way between baseline and maximal 
possible prolongation (EC50) was 181.7 ng/mL (16.0–1200.0). 
Parasitemia, present at low levels and only at baseline, was not as-
sociated with QTcF at baseline vs. day 28, at day 2 + 4 hours vs. 
day 0, or at day 2 + 4 hours vs. day 28.
Piperaquine concentration correlated with QTcF (Figure S5), 
however, post hoc analysis showed only a weak (ρ < 0.3), albeit sig-
nificant, correlation between piperaquine Cmax and D2 + 4 hours 
QTcF (Table S6). Piperaquine AUC was not correlated with day 
2 + 4 hours QTcF and ΔQTcF (Table S6). Ivermectin dose did not 
modify piperaquine’s QTcF- prolonging effect (Tables S4 and S5).
DISCUSSION
Ivermectin’s PD effect on A. gambiae mortality was much stron-
ger and persisted much longer posttreatment in the current trial 
than reported in previous studies. The PK/PD analysis showed 
that the entire 28 days of mosquitocidal effect posttreatment ob-
served in the main trial8 could be explained by ivermectin con-
centrations alone, without invoking unidentified variables, such 
as an active metabolite or a drug- drug interaction. Furthermore, 
ivermectin exerted no modification of piperaquine’s PKs or 
QTcF- prolongation. This ivermectin PK/PD model can be used 
to design new treatment regimens and predict their mosquito-
cidal effect. The methodology could also be used to assess new 
endectocides.
Ivermectin PK
Ivermectin’s PK properties in this study were similar to those 
 reported in earlier studies, which used venous concentrations 
from adults receiving single doses ranging between 150 and 
2,000 mcg/kg,7,9–14 and repeated doses up to 1,000 mcg/kg given 
three  times in 1 week.7 Ivermectin clearance has been reported 
as 19.2 L/hour (SD ± 14.8),10 17.3 L/hour (SD ± 9.2),14 and, in a 
study with co- administration of azithromycin and albendazole, as 
11.8 L/hour (RSE 32.8%) overall, and 12.3 L/hour (RSE 42.6%) 
when allowing for different subpopulations.11 Clearance in the 
current study using a simultaneous model was 10.9 L/hour for an 
average 60 kg patient (Table 1), which is similar to previous studies 
and makes a drug- drug interaction in the current study unlikely.
Ivermectin PD
Ivermectin’s mosquitocidal effect has been assessed in several in vitro 
studies with spiked blood and three previous clinical trials, one of 
which measured plasma concentrations. Outcomes are often ex-
pressed as the LC50 by a specified time postfeeding (e.g., by 7 days), 
although assay durations vary widely, as does adjustment for back-
ground mortality rate, hampering comparability. In vivo adjusted 
LC50 values in the current trial were 0.6, 2.6, 4.3, 4.7, and 7.1 
times lower than previous studies (Figure S3 and Table S3).15–18 
Noticeably, there was no major difference between the current study 
and the previous in vivo trial (adjusted LC50: 2.6 vs. 6.5 ng/mL), es-
pecially considering the later value could be an overestimation due 
to a scarcity of data in the upper ranges of concentrations (maximum 
value achieved: 15.6 ng/mL) and mosquito mortality rates (2 of 233 
Figure 2 Piperaquine pharmacokinetic model using venous and capillary concentrations: goodness- of- fit and simulation. (a) Piperaquine 
individual predicted concentrations (n = 1,581) vs. observed concentrations (n = 1,578; slope = 1.04, R2 = 0.9273). (b) Piperaquine 
population predicted concentrations vs. observed concentrations (slope = 0.93, R2 = 0.8332). (c) Weighted residual error distribution of 
predicted vs. observed piperaquine concentrations over time (mean = −0.23 over 28 days; dashed black line = locally weighted scatterplot 
smoothing (LOESS) curve fit through residuals). (d) Weighted residual error distribution of predicted vs. observed piperaquine concentrations 
over predicted ivermectin concentration (mean = −0.20 over a range of 2–1,421 ng/mL; dashed black line = LOESS curve fit through 
residuals) (e) Observed piperaquine venous concentrations (gray circles) overlaid with simulation of piperaquine 960 mg/day for 3 days (solid 
black line = median; dashed gray lines = 5% and 95% percentiles; shaded gray area = 95% confidence interval for the percentiles).  
(f) Simulation of piperaquine 960 mg/day for 3 days based on parameters derived from patients concomitantly receiving ivermectin 0 mcg/
kg/day (solid black line), ivermectin 300 mcg/kg/day (solid gray line) or ivermectin 600 mcg/kg/day (black dashed line). Conc., concentration; 
DP, dihydroartemisinin- piperaquine; lower limit of quantification, 1.5 ng/mL (horizontal gray line); PPQ, piperaquine. Simulations included 
1,000 individuals of 60 kg bodyweight.
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values were >90%).15 Any major difference between LC50 estimates 
obtained from in vivo and in vitro studies could suggest the presence 
of an active metabolite, however, comparisons between the current 
in vivo trial and the in vitro studies were inconclusive, some showing 
either lower (0.6- fold) or higher (7.1- fold) values. Nevertheless, our 
PK/PD model showed that the entire mosquitocidal effect, includ-
ing its prolonged effect beyond day 7 up to day 28 posttreatment, 
could be explained by ivermectin concentrations alone, without the 
need to invoke an unidentified metabolite (Figure 5, Table 2, and 
Figure S4). This indicates that ivermectin in its parent form is likely 
the sole contributor to the observed mosquitocidal effect for the du-
ration of the study, or if an active metabolite is present, then it must 
have a remarkably similar PK profile to ivermectin itself.
Ivermectin effect- duration
The 28- day exposure- effect relationship exceeded the predic-
tion from the pretrial PD simulation, which estimated an effect- 
duration of only 7 days.5 The simulation was based on previously 
reported 7- day LC50 value of ivermectin of 15.9 ng/mL,
17 whereas, 
in the current trial, the 7- day LC50 was 3.4 ng/mL. Importantly, 
this study also illustrated the value of using thresholds below the 
LC50 to help explain the effect- duration, such as 5% and 1% of 
maximal activity (EC5 0.83 ng/mL and EC1 0.16 ng/mL), which 
were reached at 20.1 and 28.1 days posttreatment with the 3- day 
600 mcg/kg/day regimen (Table 2). The latter is consistent with 
the observed 28- day mosquitocidal effects of the main trial.8 
Future PD simulations should consider using these EC1–EC5 con-
centrations as thresholds to predict effect- durations.
With this PK/PD model we also show that the high- dose regi-
mens can extend the time that 5% of maximal activity against mos-
quitoes is achieved from 13 days with a single- dose of 400 mcg/
kg to 23 days with the 3- day 600 mcg/kg/day regimen; addition-
ally, the overall kill rate using the 3- day 600 or 300 mcg/kg/day 
regimens is predicted to be several fold faster in the first 2 weeks 
of treatment when compared to the 400 mcg/kg single- dose 
(Figure 5).
Assessing endectocides
Other aspects of the methodology followed in this analysis may 
also be useful for further assessment and comparisons of new en-
dectocides and regimen optimization.19 We propose to collect the 
following data for each drug: Emax, Emin, EC50, Hill coefficient 
(in this study equaling 1), and PK parameters (e.g., CL, V, Q1/F, 
VP1/F, and ka) to allow for PK/PD simulation. The E is specific 
to the mosquito species studied. We also propose to express the 
PD effect of each endectocide on mosquito mortality as an inci-
dence density rate (IDR) by day 14 (i.e., deaths per 100 mosquito 
days observed, during a 14- day mosquito survival assay). The 14- 
day follow- up is required to capture the cumulative effect during 
a prolonged extrinsic cycle. The use of IDRs instead of hazard 
ratios (HRs) is recommended, as rates are easier to interpret and 
incorporate in PK/PD models. For example, in the PK/PD simu-
lation it was possible to simulate an IDR for any desired drug reg-
imen at any time posttreatment. By dividing the drug IDR (E) by 
the baseline mortality rate (Emin) it was then possible to calculate 
the incidence rate ratio (IRR = E/Emin) at each timepoint (see 
IVERMAL dose-response calculator (Text S3) and Figure 5d). 
Both IRRs and HRs assess the relative differences in incidence 
rates, can be interpreted in roughly the same way,20 and equally 
incorporated into population models. As MDA rounds are likely 
to be spaced at least 1 month apart, determining an endectocide’s 
IRR at 28 days posttreatment (either directly or by simulation) 
may be a useful measure to assess prolonged effectiveness.
Ivermectin capillary concentrations
No previous studies assessed capillary concentrations of ivermec-
tin; the current study identified a capillary- venous ratio of 1.33 
(0.98–1.63) ± 29.1%, which was consistent over time from days 
2–7 posttreatment (Table 1 and Figure S2). In the current as-
says, mosquitoes were fed venous blood via artificial membranes. 
As capillary concentrations of ivermectin were found to be higher 
(Table 1), and when mosquitoes bite humans directly they are 
more likely to feed from capillary blood, the mosquitocidal effects 
of ivermectin might be higher than presented in the current study. 
To assess this, an analysis is ongoing comparing mosquito mortal-
ity following direct skin feeding (from capillary blood) vs. mem-
brane feeding (from venous blood).
Piperaquine PK
Piperaquine PKs have been described using meta- analysis, 
across age groups, and using capillary sampling, with clearance 
reported as 55.4 L/hour (RSE 4.2%; for an average 54 kg pa-
tient),21 which was somewhat higher in the current study at 
97.1 L/hour (interindividual variability ± 49.1%; for an average 
60 kg patient). The majority of previous studies were performed 
in Asian patients, whereas this study was performed in Kenyan 
patients. Although the current clearance value had a relatively 
wide percentile range (p5–p95: 20.0–177.3), more studies 
in African patients might be needed to investigate whether 
genetics plays a role in piperaquine clearance. The plasma 
capillary- venous ratio of 1.55 ± 36.1% was similar to those re-
ported previously for blood (1.66)22 and plasma (1.9,23 1.63,24 
and 1.4125). Using a linear model, piperaquine’s PD effect on 
QT- interval was also similar to previous studies,26–29 with the 
current trial predicting a ΔQTcF- prolongation of 3.71 ms (95% 
CI: 3.12–4.29) per 100 ng/mL of piperaquine. Additionally, 
using a dynamic Emax model that simultaneously incorporated 
piperaquine PK and PD data, we estimated maximal QTcF 
(449.8 ms) and maximal ΔQTcF (53.5 ms) using population 
methods (Table S5 and Figure S5). Importantly, neither of the 
two ivermectin regimens used in the study altered piperaquine’s 
PKs or PDs (Table 1, Figure 2f, Tables S4 and S5).
Drug interaction
It is not possible to completely rule out an effect of DP on ivermec-
tin’s PKs or PDs, as all groups received DP. Nonetheless, a substan-
tial drug- drug interaction is unlikely as ivermectin PK parameters 
were very similar to previously reported values (Table 1) and 
within our prediction, which was based on published data where 
ivermectin was given alone.5 Future studies comparing ivermectin 
alone vs. ivermectin with DP could help to further assess any po-
tential effect of DP on ivermectin PK/PD.
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Limitations and future studies
A limitation of this PK/PD analysis was that the lower limit of 
quantification (LLOQ) for ivermectin was relatively high (ve-
nous: 5 ng/mL, capillary: 10 ng/mL), resulting in undetectable 
concentrations for 34% of venous and 20% of capillary samples 
in the ivermectin arms posttreatment, predominantly at later 
timepoints. Previous studies used venous LLOQs of: 0.2,30 1.0,31 
0.5,7 2.5,11 0.2,15 and 0.8,32 ng/mL. Based on the number of sam-
ples available, it was still possible to generate an accurate PK/
PD model, however, future studies should attempt to use assays 
with lower LLOQs to make full use of the available samples and 
detect ivermectin at the very low concentrations that it still has 
a mosquitocidal effect. Another possible limitation is that this 
study used a homogeneous laboratory- reared mosquito colony, 
which may not be reflective of wild populations. Although pre-
vious work has demonstrated that ivermectin affects survival of 
all tested anophelines (≥ 17 species tested),33 future studies would 
be beneficial to examine possible (heterogeneity of) effects of iv-
ermectin against wild populations.8 Finally, this study included 
only (nonpregnant) adults, whereas the targeted population for 
MDA also includes children and pregnant women. Children 
are hypothesized to have faster ivermectin metabolism based on 
increased CYP3A4 expression.34 Ivermectin is currently contra- 
indicated in pregnancy, however, inadvertent exposures during 
MDA for lymphatic filariasis and onchocerciasis have not led to 
an increase in adverse events.35 Further studies assessing the safety, 
efficacy, and PKs of (high- dose) ivermectin are needed in children 
and pregnant women.
Prolonging mosquitocidal effects
Additional effort is also required to further increase ivermectin’s 
effect- duration beyond 28 days, as a longer effect- duration would 
allow MDA rounds to be more widely spaced and reduced in num-
ber. Consideration could be given to developing slow- release tablet 
formulations, to developing gastric- resident devices,36 or to other 
similar drugs with a long half- life, such as moxidectin, albeit its 
LC50 of 2,789 ng/mL against A. gambiae does not seem to make it 
very suited for malaria control.12,37
CONCLUSION
In conclusion, the current PK/PD model predicted that the mos-
quitocidal effect of high- dose ivermectin lasted for at least 28 days 
posttreatment, which is consistent with the in vivo observations 
from the main trial.8 This effect could be explained by ivermec-
tin concentrations alone, without invoking unidentified vari-
ables, such as an active metabolite or a drug- drug interaction. 
Furthermore, ivermectin exerted no modification of piperaquine’s 
Figure 3 (a) Relationship between observed ivermectin venous 
concentration and mosquito mortality rate (/100 days). Open circles 
(n = 246 concentrations above lower limit of quantification (LLOQ) 
with paired mortality rate) represent observed data. The solid line 
represents sigmoidal three- parameter maximum effect (Emax) fit. 
(b) Similar to a, however, now overlaid with predicted ivermectin 
venous concentrations for all samples (including those that were 
below LLOQ) with observed mosquito mortality rates in patients 
that received ivermectin (gray squares, n = 567). The dashed line 
represents the sigmoidal three- parameter Emax fits for the predicted 
concentrations. (c) A comparison between the exposure relationship 
of a, b, and the exposure- effect relationship generated using the 
simultaneous pharmacokinetic/pharmacodynamic (PK/PD) model, 
which incorporated PD data in the process of PK modeling and vice 
versa. IVM, ivermectin; conc., concentration.
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PKs or QTcF- prolongation. The presented ivermectin PK/PD 
model can be used to design new treatment regimens and predict 
their mosquitocidal effect. The presented methodology may be 
useful for the assessment of new endectocides.
METHODS
Trial design
Details of the trial design, procedures, and main results were pub-
lished elsewhere.5,8 Briefly, the study was a randomized, double- 
blind, placebo- controlled, parallel three- arm, superiority trial 
(ClinicalTrials.gov: NCT02511353). One hundred forty- one 
adults with uncomplicated malaria in western Kenya were ran-
domly assigned (1:1:1), stratified by sex and body mass index, to 
receive 3 days of ivermectin 600 mcg/kg/day (n = 47), 300 mcg/
kg/day (n = 48), or placebo (n = 46), all co- administered with 
3 days of DP. The primary outcome was the effect of ivermectin 
dose on mosquito mortality. For safety, the effect of ivermectin 
dose on piperaquine concentration and piperaquine- induced 
QTcF- prolongation were also assessed. Venous plasma was 
collected from day 0 to day 28 using both rich and population 
sampling strategies. Additional capillary plasma was collected 
using finger- pricks from day 2 + 4 hours (4 hours after the third 
dose) up to day 7, concomitantly with the venous population sam-
pling. Capillary sampling might be useful for subsequent pediat-
ric or field trials and might be more representative of the blood 
that mosquitoes feed on.
Observed plasma concentrations and outcome data
During 28 days of follow- up, 1,393 venous and 335 paired capil-
lary plasma samples, 850 mosquito- cluster mortality rates (from 
91,109 mosquitoes), and 524 QTcF- intervals were collected 
(Table S2). Drug analytical quantification was performed by liq-
uid chromatography tandem mass spectrometry (Text S1); only 
quantifiability and not detectability was considered. Ivermectin 
venous concentrations were above the LLOQ (5 ng/mL) for 534 
samples, of which 246 had paired mortality rates, and capillary 
concentrations were above the LLOQ (10 ng/mL) for 181 sam-
ples. Piperaquine venous concentrations were above the LLOQ 
Table 2 PD parameters of ivermectin. 
Models based on:
Observed data:  
obs. venous conc. vs.  
obs. mosq. effect  
(pooled analysis)
Sequential PK/PD model:  
pred. venous conc. vs.  
obs. mosq. effect  
(pooled analysis)
Simultaneous PK/PD model: 
pred. venous conc. vs.  
pred. mosq. effect  
(population modeling)
Parameter Median (p5–p95) Median (p5–p95) Median (p5–p95)
Mosquitocidal effect
Emin (deaths/100 days) 3.7 (fixed) 3.7 (fixed) 3.9 (2.9–5.8)
E1 (deaths/100 days) 4.18 (4.16–4.21) 4.22 (4.19–4.25) 4.40 (4.23–4.53)
E5 (deaths/100 days) 6.14 (6.02–6.25) 6.31 (6.18–6.47) 6.38 (5.54–7.08)
E50 (deaths/100 days) 28.1 (23.2–29.3) 29.9 (28.5–31.4) 28.7 (20.1–35.5)
E95 (deaths/100 days) 50.1 (47.7–52.3) 53.4 (50.8–56.2) 50.7 (34.9–64.1)
Emax + Emin 
(deaths/100 days)
52.5 (50.0–54.9) 56.0 (53.3–59.0) 53.4 (36.7–67.5)
Effective concentration
EC1 (ng/mL) 0.11 (0.095–0.14) 0.17 (0.14–0.19) 0.16 (0.053–0.37)
EC5 (ng/mL) 0.90 (0.51–1.14) 0.84 (0.74–1.0) 0.83 (0.28–1.9)
EC50 (ng/mL) 11.3 (9.5–13.6) 16.5 (14.1–19.2) 15.9 (5.3–36.4)
EC95 (ng/mL) 214.3 (178.2–259.0) 314 (269.3–374.3) 302.1 (100.7–691.6)
Time above EC (ivermectin 300 mcg/kg/day for 3 days)
T1 (days) 33.3 (19.0–130.5) 30.1 (17.9– 115.4) 24.4 (10.5–63.0)
T5 (days) 22.6 (13.4–56.4) 20.3 (12.2–50.9) 17.0 (8.0–42.6)
T50 (days) 5.6 (2.4–12.7) 3.9 (2.2–8.9) 4.1 (NA–8.1)
T95 (days) NA NA NA
Time above EC (ivermectin 600 mcg/kg/day for 3 days)
T1 (days) 38.0 (21.6–150.1) 34.5 (20.0–142.2) 28.1 (11.5–72.8)
T5 (days) 27.4 (15.4–66.0) 24.8 (14.3–60.4) 20.1 (9.3–52.9)
T50 (days) 9.0 (3.0–20.7) 7.1 (2.6–16.4) 6.8 (2.5–14.7)
T95 (days) NA NA NA
Emin was fixed to 3.7 for (i) and (ii) based on baseline and control mortality. Exx is the percentile of effect between Emin and Emin + Emax. ECxx is the concentration 
at which Exx is achieved. Txx is the time posttreatment at which ECxx and Exx are achieved.
Conc., concentration; EC, effective concentration; Emin, minimum effect; Emax, maximum effect relative to Emin; mosq. mosquitocidal; Obs., observed; PD, 
pharmacodynamic; PK, pharmacokinetic; pred., predicted.
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(1.5 ng/mL) for 1,246 samples, of which 251 had paired QTcF- 
intervals, and capillary concentrations were above the LLOQ 
(1.5 ng/mL) for 333 samples.
PK and PD analysis
Pooled exposure- effect analyses were performed using Prism 
v7.00 (GraphPad Software, La Jolla, CA). Population PK/PD 
modeling and fitting of data were independently performed 
for ivermectin and piperaquine concentrations using Pmetrics 
v1.5.0 (LAPKB, University of Southern California, Los Angeles, 
CA).38 All PK and PK/PD modeling done with Pmetrics utilized 
the nonparametric adaptive grid for finding the nonparametric 
maximum likelihood estimate of the population distribution. 
Samples that were BLOQ were indicated in the Pmetrics data file 
as “- 99” and the LLOQ was incorporated into the overall stan-
dard population error model. A proportional scaling factor was 
used to fit venous and capillary concentrations simultaneously 
for each drug model (Eqs. S1–S13 in Text S2).
Residual analysis was performed for all predicted PK and PD 
data in Pmetrics. This included goodness- of- fit comparisons of 
Figure 4 The exposure- effect relationship between predicted ivermectin (IVM) concentrations (from the sequential pharmacokinetic (PK) 
model, using PK data from all days) and corresponding observed mosquito mortality rates separated by day of analysis after initiation of 
treatment. Minimum effect (Emin) and maximum effect (Emax) were fixed to the values determined by analyzing the entire dataset and half- 
maximal effective concentration (EC50) concentrations (95% confidence intervals) were estimated as shown in the figure.
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individual and population predictions against observed data, as 
well as weighted residuals over time and concentration, to investi-
gate any biases toward higher concentrations or later timepoints. 
The VPCs were performed using the Pmetrics simulator tool, 
in which 1,000 subjects were simulated based on the generated 
median PK parameters, their variances and correlation matri-
ces as generated in Pmetrics for each drug. Additionally, weight 
variation among patients and associated dosing brackets were in-
cluded in the simulation. The weight variation was set to match 
that of the study population and a median of 60 kg patient weight 
were used for the simulation. The Pmetrics simulator predicted 
patients’ weights for 1,000 patients in the range of 45–101 kg, 
which is the range of this study. The median, 5%, and 95% per-
centiles with their 95% CIs were plotted against observed data 
Figure 5 Ivermectin pharmacokinetic (PK) and pharmacodynamic (PD) simulation of mosquito mortality rate (using simultaneous approach) 
with (a) 300 mcg/kg/day for 3 days, and (b) 600 mcg/kg/day for 3 days. Mosquito mortality rate simulated median (solid black line), 5th and 
95th percentiles (dashed lines), and 95% confidence intervals (CIs; shaded gray areas), with observed mosquito mortality rates per sample 
(open circles), observed median ± interquartile range mortality rate per study visit (ball- whiskers), and minimum effect (Emin; horizontal dashed 
line). (c) Comparison of both regimens with a simulation of a 400 mcg/kg single- dose. Simulations included 1,000 individuals of 60 kg 
bodyweight. (d) Mortality rate ratios calculated as incidence rate ratios using the PK/PD model (incidence rate ratio; lines) and as hazard 
ratios (HRs) with 95% CIs as per main efficacy results8 (HR; triangles: 600 mcg/kg/day for 3 days vs. placebo, squares: 300 mcg/kg/day for 
3 days vs. placebo, and whiskers: 95%CIs). Conc., concentration; PPQ, piperaquine.
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for the VPC graphs. A similar simulation was done using a si-
multaneous PK/PD model with 1,000 subjects to predict the 
overall mosquitocidal activity in the study population. To avoid 
the complexity of adding different dosing brackets to different 
patient weights, simulations were performed with a standard pa-
tient weight only, which is 600 mcg/kg/day or 300 mcg/kg/day 
administered to 60 kg patients. The wide margins used for CL/F 
and V/F would account for more variability than that introduced 
by variability in weight.
Ivermectin PK/PD analysis
Modeling ivermectin was performed using multiple approaches 
to address several questions about its PK/PD relationship against 
mosquitoes. As it had been hypothesized that ivermectin’s mos-
quitocidal effects at later timepoints could be due a metabolite or 
drug- drug interaction, an initial sequential analysis (using three 
approaches, see below) was performed to justify a final simulta-
neous analysis. The sequential analysis, in which the PK model 
is blinded to PD data, assessed the consistency of ivermectin’s 
exposure- effect relationship over time. The simultaneous analysis 
presumes ivermectin concentrations alone can explain the mos-
quitocidal activity; this allows for the model to predict best PK 
and PD parameter estimates using both PK and PD data simulta-
neously to achieve well- informed parameters that are derived from 
two sets of data (PK and PD data) rather than parameters being 
informed by a single set of data (i.e., PK information only, as in the 
first step of the sequential model).
Sequential modeling approach. For both the sequential and 
simultaneous approaches, PK analysis was performed using a 
two- compartment model (Figure S1), which displayed a better fit 
than a one- compartment model (Table S1). A three- compartment 
model fit was not attempted for ivermectin as VPCs showed that 
ivermectin follows a two- compartment model trend and does not 
display a tri- exponential trend. The two- compartment PK model 
was performed using Eqs. S1–S13 in Text S2.
PD analysis of the relationship between ivermectin concentra-
tions and mosquitocidal effect was performed according to the fol-
lowing Emax sigmoidal equation
39:
Where E represents the mosquitocidal effect of ivermectin ex-
pressed as the mortality rate of mosquitoes per 100 days, Emin is the 
baseline natural mortality rate, Emax is the maximal possible effect 
relative to Emin, EC50 is the concentration necessary to achieve a 
rate halfway between baseline and maximal effect (Emax + Emin), 
and C is ivermectin concentration in grams/liter.
The sequential PD analysis was performed using three ap-
proaches. The first was fitting an Emax function through observed 
mosquito mortality rates and pooled observed concentrations in 
Prism v7. The second followed the same methodology using pre-
dicted concentrations in order to assess whether (BLOQ) con-
centrations predicted by the Pmetrics PK model (blinded to PD 
data) showed a similar exposure- effect relationship to observed 
concentrations. The third approach used Pmetrics for the popula-
tion modeling of both PK and PD separately, in which each patient 
in the PD analysis had fixed PK parameters that matched their in-
dividual predicted parameters in the PK run. This allowed predict-
ing population variability on PD parameters using the sequential 
PK/PD model (which cannot be assessed using pooled data in the 
previous two approaches).
The relationship between ivermectin exposure and its mosqui-
tocidal effect was investigated separately for each day of the study 
(days: 2 + 4 hours, 7, 10, 14, 21, and 28), using predicted PK pa-
rameters (second sequential model), as any time- dependent vari-
ation could potentially suggest the presence of an unidentified 
mosquitocidal metabolite.
Simultaneous modeling approach. The simultaneous approach 
used the same equations above, however, all available PD data 
(ivermectin mosquito mortality rates) were entered into the 
initial modeling process and both the PK and the PD data for all 
subjects were modeled simultaneously, allowing for PD data to 
enhance the PK fit, and vice versa, based on the assumption that 
ivermectin in its parent form is solely responsible for any increase 
in the mosquito mortality rate throughout the study duration.
Piperaquine PK
Piperaquine PK was analyzed using a three- compartment model 
(Figure S1) according to Eqs. S1–S13 in Text S2. This was com-
pared to one- compartment and two- compartment models, which 
resulted in poorer fits as evidenced from −2 log- likelihood and 
Akaike information criterion and Bayesian information criteria 
(Table S1).
Piperaquine PD
Piperaquine effect upon QTcF- interval was analyzed using two 
methods: (i) a linear model, according to Eq. 2 below, which is 
commonly used in similar published analyses, and (ii) an Emax 
sigmoidal model, utilizing previously discussed Eq. 1, with the 
effect (E) being QTcF- interval in milliseconds at any given con-
centration, and C being piperaquine concentration. The data was 
either analyzed using pooled observed piperaquine concentration 
vs. QTcF- interval (linear model) or simultaneously fitted using a 
population method with Pmetrics, as described for the simultane-
ous ivermectin PK/PD model (Emax model).
The slope represents the relationship between piperaquine 
concentration in ng/mL and the change in QTcF (∆QTcF) in 
milliseconds.
Secondary PK parameters post hoc statistical analysis
AUC0–28 days is defined as the predicted area under the curve for 
3 doses of ivermectin or piperaquine over a period of 28 days and 
was determined using the AUC trapezoidal approximation algo-
rithm in Pmetrics for each subject individually. The Cmax rep-
resents the maximal predicted concentration for each subject in 
the study. The Tmax is the time at which Cmax is achieved for each 
(1)E=
Emax ⋅C
EC50+C
+Emin
(2)ΔQTcF= intercept+ slope ⋅C
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individual and t1/2 is calculated from the predicted PK slope for 
each individual between 27 and 29 days after treatment.
The primary PK parameters for ivermectin (ka, Q1/F, VP1/F, 
CL/F, and V/F) and primary PK parameters for piperaquine (ka, 
Q1/F, VP1/F, Q2/F, VP2/F, CL/F, and V/F) and secondary PK pa-
rameters for both drugs (Cmax and AUC0–28 days) for each subject 
in the study were correlated to each other as well as with age, sex, 
weight, height, QTcF interval (measured at days 0, 2, 2 + 4 hours, 
and 28 after dosing initiation) or mosquito mortality rate (at 
each study timepoint). Correlation analysis was done using SPSS 
v.24 (IBM, Armonk, NY) using Spearman bivariate correlation 
to identify any possible effects that require further analysis. This 
included any effect of ivermectin exposure upon piperaquine, 
exploring any possible interaction between study arm (i.e., iver-
mectin dose 0, 300, or 600 mcg/kg/day), interaction between 
all structural parameters (e.g., CL, V, Q1/F, VP1/F, and ka), and 
interaction between observed and predicted Cmax, and AUC for 
both drugs. Correlations were considered significant if ρ > 0.3 
and P < 0.05.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com)
Figure S1. Flowchart of pharmacokinetic model applied sepa-
rately to both ivermectin and piperaquine.
Figure S2. Capillary vs. venous concentration ratios for iver-
mectin and piperaquine.
Figure S3. Ivermectin vs. mosquito mortality (%) dose- 
response curves (LC50 method).
Figure S4. Residual analysis of mosquito mortality rates (i.e., 
ivermectin’s pharmacodynamic effect) over time, as predicted 
by the simultaneous PK/PD model vs. observed data.
Figure S5. Piperaquine vs. QTcF dose-response curves.
Table S1. Compartmental model fits for ivermectin and 
piperaquine.
Table S2. Number of observed concentrations and outcomes 
(ivermectin and piperaquine).
Table S3. Ivermectin LC50 values by assay duration, and vs. 
previous studies.
Table S4. Piperaquine concentration and QTcF interval (ob-
served data).
Table S5. Piperaquine concentration and QTcF interval (popu-
lation fitted data).
Table S6. Correlations.
Text S1. Methods for drug analytical quantification of ivermec-
tin and piperaquine.
Text S2. Equations.
Text S3. IVERMAL dose-response calculator.
ACKNOWLEDGMENTS
Many thanks to all those who made this study possible, including 
the study participants and staff, the members of the Trial Steering 
Committee (Teun Bousema, Kevin Kobylinski, and Brian Foy), and 
of the Data Monitoring & Ethics Committee (Alejandro Krolewiecki, 
James Oloo, Timothy Collier, and Carlos Chaccour). Further thanks to 
the Mundo Sano Foundation and Elea Laboratories for donating the iv-
ermectin, and NeurOptics for donating pupillometers. Finally, we would 
also like to thank the Jaramogi Oginga Odinga Teaching and Referral 
Hospital (JOOTRH) and the Kisumu County Ministry of Health (MoH), 
for hosting the study, Donald Tjia, Ophthalmologist, for his support, 
and Jacco Veldhuyzen, Emergency Medicine Physician, for assisting in 
interpreting electrocardiograms. This article is published with the per-
mission of KEMRI Director. The findings and conclusions in this article 
are those of the authors and do not necessarily represent the official 
position of the US Centers for Disease Control and Prevention.
FUNDING
This study is funded by the Malaria Eradication Scientific Alliance 
(MESA), through a sub- grant from the Bill and Melinda Gates 
Foundation (BMGF). Neither MESA nor the BMGF had any role in 
the design of the study, the collection, analysis, and interpretation 
of data, or in the writing the manuscript. Co- funding was provided 
by the US Centers for Disease Control and Prevention, through a 
Cooperative Agreement between the CDC and LSTM.
CONFLICTS OF INTEREST
The authors declared no competing interests for this work.
AUTHOR CONTRIBUTIONS
M.R.S., E.O.O., Da.W., T.K.K., B.O.A., T.B., N.M.B., J.E.G., A.M.S., 
M.R.D., P.A.P.H., S.K.K., Du.W., F.O.t.K., S.A.W., and G.A. wrote the 
manuscript. M.R.S., G.A., E.O.O., S.A.W., and F.O.t.K. designed the 
research. M.R.S., E.O.O., T.K.K., B.O.A., and Da.W. performed the 
research. M.R.S. and G.A. analyzed the data. Da.W. and S.A.W. con-
tributed new reagents/analytical tools.
© 2018 The Authors Clinical Pharmacology & Therapeutics published  
by Wiley Periodicals, Inc. on behalf of American Society for Clinical 
Pharmacology and Therapeutics.
This is an open access article under the terms of the Creative Commons 
Attribution NonCommercial License, which permits use, distribution and 
reproduction in any medium, provided the original work is properly cited 
and is not used for commercial purposes.
 1. Eisele, T.P. et al. Short- term impact of mass drug administration 
with dihydroartemisinin plus piperaquine on malaria in Southern 
province Zambia: a cluster- randomized controlled trial. J. Infect. 
Dis. 214, 1831–1839 (2016).
 2. Mwesigwa, J. et al. Mass drug administration and reactive case 
detection for malaria elimination. ASTMH 2017 session. Am. J. 
Trop. Med. Hyg. 97(suppl. 5), 411–413 (2017).
 3. von Seidlein, L. et al. Targeted malaria elimination in the greater 
Mekong subregion using mass drug administration. ECTMIH 2017 
Session. Trop. Med. Int. Health 22, 394–396 (2017).
 4. Chaccour, C.J. et al. Ivermectin to reduce malaria transmission: a 
research agenda for a promising new tool for elimination. Malar. J. 
12, 153 (2013).
 5. Smit, M.R. et al. Efficacy and safety of high- dose ivermectin for 
reducing malaria transmission (IVERMAL): protocol for a double- 
blind, randomized, placebo- controlled, dose- finding trial in 
Western Kenya. JMIR Res. Protoc. 5, e213 (2016).
 6. Gardon, J., Boussinesq, M., Kamgno, J., Gardon-Wendel, N., 
Demanga, N. & Duke, B.O. Effects of standard and high doses of 
ivermectin on adult worms of Onchocerca volvulus: a randomised 
controlled trial. Lancet 360, 203–210 (2002).
 7. Guzzo, C.A. et al. Safety, tolerability, and pharmacokinetics of 
escalating high doses of ivermectin in healthy adult subjects. J. 
Clin. Pharmacol. 42, 1122–1133 (2002).
 8. Smit, M.R. et al. Safety and mosquitocidal efficacy of high- dose 
ivermectin when co- administered with dihydroartemisinin- 
piperaquine in Kenyan adults with uncomplicated malaria 
(IVERMAL): a randomised, double- blind, placebo- controlled trial. 
Lancet Infect. Dis. 18, 615–626 (2018).
CLINICAL PHARMACOLOGY & THERAPEUTICS | VOLUME 105 NUMBER 2 | FEBRUARY 2019 401
CLINICAL TRIAL
 9. Gonzalez Canga, A., Sahagun Prieto, A.M., Diez Liebana, M.J., 
Fernandez Martinez, N., Sierra Vega, M. & Garcia Vieitez, J.J. The 
pharmacokinetics and interactions of ivermectin in humans—a 
mini- review. AAPS J. 10, 42–46 (2008).
 10. Amsden, G.W., Gregory, T.B., Michalak, C.A., Glue, P. & Knirsch, 
C.A. Pharmacokinetics of azithromycin and the combination of 
ivermectin and albendazole when administered alone and concur-
rently in healthy volunteers. Am. J. Trop. Med. Hyg. 76, 1153–1157 
(2007).
 11. El-Tahtawy, A., Glue, P., Andrews, E.N., Mardekian, J., Amsden, 
G.W. & Knirsch, C.A. The effect of azithromycin on ivermectin 
pharmacokinetics—a population pharmacokinetic model analysis. 
PLoS Negl. Trop. Dis. 2, e236 (2008).
 12. Prichard, R., Menez, C. & Lespine, A. Moxidectin and the avermec-
tins: consanguinity but not identity. Int. J. Parasitol. Drugs Drug 
Resist. 2, 134–153 (2012).
 13. Miyajima, A. et al. Effect of high- fat meal intake on the pharmaco-
kinetic profile of ivermectin in Japanese patients with scabies. J. 
Dermatol. 43, 1030–1036 (2016).
 14. Munoz, J. et al. Safety and pharmacokinetic profile of fixed- dose 
ivermectin with an innovative 18 mg tablet in healthy adult volun-
teers. PLoS Negl. Trop. Dis. 12, e0006020 (2018).
 15. Ouedraogo, A.L. et al. Efficacy and safety of the mosquitocidal 
drug ivermectin to prevent malaria transmission after treatment: 
a double- blind, randomized, clinical trial. Clin. Infect. Dis. 60, 
357–365 (2015).
 16. Kobylinski, K.C. et al. The effect of oral anthelmintics on the 
survivorship and re- feeding frequency of anthropophilic mosquito 
disease vectors. Acta Trop. 116, 119–126 (2010).
 17. Kobylinski, K.C., Foy, B.D. & Richardson, J.H. Ivermectin inhibits 
the sporogony of Plasmodium falciparum in Anopheles gambiae. 
Malar. J. 11, 381 (2012).
 18. Fritz, M.L., Siegert, P.Y., Walker, E.D., Bayoh, M.N., Vulule, J.R. & 
Miller, J.R. Toxicity of bloodmeals from ivermectin- treated cattle to 
Anopheles gambiae s.l. Ann. Trop. Med. Parasitol. 103, 539–547 
(2009).
 19. Burrows, J.N. et al. New developments in anti- malarial target can-
didate and product profiles. Malar. J. 16, 1–29 (2017).
 20. Hernan, M.A.. The hazards of hazard ratios. Epidemiology 
(Cambridge, MA). 21, 13–15 (2010).
 21. Hoglund, R.M. et al. Population pharmacokinetic properties of 
piperaquine in falciparum malaria: an individual participant data 
meta- analysis. PLoS Med. 14, e1002212 (2017).
 22. Ashley, E.A. et al. Comparison of plasma, venous and 
capillary blood levels of piperaquine in patients with un-
complicated falciparum malaria. Eur. J. Clin. Pharmacol. 66, 
705–712 (2010).
 23. Tarning, J. et al. Population pharmacokinetics and pharmacody-
namics of piperaquine in children with uncomplicated falciparum 
malaria. Clin. Pharmacol. Ther. 91, 497–505 (2012).
 24. Zongo, I. et al. Efficacy and day 7 plasma piperaquine concen-
trations in African children treated for uncomplicated malaria 
with dihydroartemisinin- piperaquine. PLoS One 9, e103200 
(2014).
 25. Tarning, J. et al. Population pharmacokinetics and antimalarial 
pharmacodynamics of piperaquine in patients with plasmodium 
vivax malaria in Thailand. CPT Pharmacometrics Syst. Pharmacol. 3, 
e132 (2014).
 26. Vanachayangkul, P. et al. Piperaquine population pharmacokinet-
ics and cardiac safety in Cambodia. Antimicrob. Agents Chemother. 
61, pii: e02000-16 (2017).
 27. Chotsiri, P. et al. Population pharmacokinetics and 
 electrocardiographic effects of dihydroartemisinin- piperaquine 
in healthy volunteers. Br. J. Clin. Pharmacol. 83, 2752–2766 
(2017).
 28. Darpo, B. et al. Evaluation of the QT effect of a combination of 
piperaquine and a novel anti- malarial drug candidate OZ439, for 
the treatment of uncomplicated malaria. Br. J. Clin. Pharmacol. 80, 
706–715 (2015).
 29. Wattanakul, T. et al. Population pharmacokinetics and 
 cardiovascular safety of piperaquine in African patients with 
uncomplicated malaria. Annual Meeting of the Population 
Approach Group in Europe 2017. <http://www.page-meeting.
org/?abstract=7242>.
 30. Edwards, G., Dingsdale, A., Helsby, N., Orme, M.L. & 
Breckenridge, A.M. The relative systemic availability of ivermectin 
after administration as capsule, tablet, and oral solution. Eur. J. 
Clin. Pharmacol. 35, 681–684 (1988).
 31. Krishna, D.R. & Klotz, U. Determination of ivermectin in 
human plasma by high- performance liquid chromatography. 
Arzneimittelforschung 43, 609–611 (1993).
 32. Kobylinski, K. et al. Pharmacokinetic and pharmacodynamic 
properties of ivermectin: ivermectin for malaria in Southeast Asia 
(IMSEA), Thailand. American Society of Tropical Medicine and 
Hygiene Annual Meeting; Baltimore, MD (2017).
 33. Chaccour, C.J. et al. Establishment of the Ivermectin Research 
for Malaria Elimination Network: updating the research agenda. 
Malar. J. 14, 243 (2015).
 34. Upreti, V.V. & Wahlstrom, J.L. Meta- analysis of hepatic cytochrome 
P450 ontogeny to underwrite the prediction of pediatric pharmaco-
kinetics using physiologically based pharmacokinetic modeling. J. 
Clin. Pharmacol. 56, 266–283 (2016).
 35. Brown, K.R. Changes in the use profile of Mectizan: 1987- 1997. 
Ann. Trop. Med. Parasitol. 92(Suppl 1), S61–S64 (1998).
 36. Bellinger, A.M. et al. Oral, ultra- long- lasting drug delivery: ap-
plication toward malaria elimination goals. Sci. Transl. Med. 8, 
365ra157 (2016).
 37. Butters, M.P. et al. Comparative evaluation of systemic drugs for 
their effects against Anopheles gambiae. Acta Trop. 121, 34–43 
(2012).
 38. Neely, M.N., van Guilder, M.G., Yamada, W.M., Schumitzky, A. & 
Jelliffe, R.W. Accurate detection of outliers and subpopulations 
with Pmetrics, a nonparametric and parametric pharmacometric 
modeling and simulation package for R. Ther. Drug Monit. 34, 
467–476 (2012).
 39. Holford, N.H. & Sheiner, L.B. Understanding the dose- effect rela-
tionship: clinical application of pharmacokinetic- pharmacodynamic 
models. Clin. Pharmacokinet. 6, 429–453 (1981).
